I had the idea of something called Prostate cancer postcards. In a few days it will be the 5-year anniversary of my diagnosis with a very serious form of prostate cancer. So far since then I’ve been doing pretty well (knock on wood). I am still getting PSA tested and life still has a cancer thread […]
Prostate cancer postcards Read More »
The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many
CIRM 2.0 Should Include Bridges Training Program Read More »
This post is the first in a series about the Clinicaltrials.gov website. This piece is an interview the Director, Dr. Deborah Zarin. I want to thank her for taking the time to answer my questions. Later, I will post Part 2 in which I discuss my concerns about the trend of for-profit stem cell clinic trials
Interview with Clinicaltrials.gov Director Deborah Zarin Read More »
Sperm and brain tumors? Sometimes in science there are unexpected threads tying seemingly very different things together. Unraveling the knots in these threads can lead to new insights into important developmental processes and mechanisms of disease. My lab studies epigenomic and transcription factors including a molecule called histone variant H3.3 (more here on H3.3). H3.3
What is the connection between sperm and brain tumors? Read More »
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently
ACT reinventing itself with new name Ocata Therapeutics Read More »
The reviews of a STAP paper submitted to and rejected by the journal Science in 2012 were posted at Retraction Watch yesterday. They filled in some gaps in the puzzle of the series of events that led to such flawed science being published in Nature in January 2014, but the reviews also raised more questions. Today, more STAP paper
STAP papers blistered by Nature’s own reviewers were then accepted Read More »
Before the two STAP cell papers were published in Nature in January of 2014, much of the same data was reportedly submitted as single papers to other high-profile journals including Science. In these cases, the proto-STAP papers as we might call them were rejected. But why? Until now we largely could only speculate. However, the reviews
Full Reviews of Rejected STAP Paper Point to Early Signs of Big Trouble Read More »
The last two years at Nature Magazine have seen a surprising wave of paper retractions. In 2013 and now just so far in 2014, Nature has retracted a total of 14 papers. How unusual is that? Historically, Nature retracts relatively few papers, perhaps just under two per year on average. What the heck has been going on in 2013-2014? Let’s break it
Could Nature’s 2-year torrent of paper retractions be a good thing? Read More »
Who should you follow on Twitter amongst all the biologists out there? Actually, it very much depends on your interests and what you want to get out of it. Below is my list of top biologists/biology writers that I, with all my many biases (see below) recommend to you to follow on Twitter, in no particular order (actually
A List of Top Biologists to Follow on Twitter Read More »
Nikkei is reporting that the RIKEN internal attempt to replicate so-called STAP (acid bath) cells has failed. Update: apparently, although RIKEN calls the efforts preliminary, the team tried to make STAP an amazing 22 times and 22 times it failed. The rumors for weeks in the stem cell gapevine that RIKEN itself could not get
RIKEN fails to reproduce STAP, big CDB shake up expected Read More »